GT200000069A - Derivados heterociclicos utiles como agentes anticancerosos. - Google Patents

Derivados heterociclicos utiles como agentes anticancerosos.

Info

Publication number
GT200000069A
GT200000069A GT200000069A GT200000069A GT200000069A GT 200000069 A GT200000069 A GT 200000069A GT 200000069 A GT200000069 A GT 200000069A GT 200000069 A GT200000069 A GT 200000069A GT 200000069 A GT200000069 A GT 200000069A
Authority
GT
Guatemala
Prior art keywords
useful
target agents
derivatives
heterociclic
amida
Prior art date
Application number
GT200000069A
Other languages
English (en)
Inventor
Thomas George Gant
Mark Carl Noe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200000069A publication Critical patent/GT200000069A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

ESTA INVENCION SE REFIERE A DERIVADOS NOVEDOSOS DE ISOTIAZOL (VER FORMULA I, (DONDE "Z" REPRESENTA S,O, O NR; "X" ES: N O CR; "R" ES: ESTER, AMIDA, AMIDA SUSTITUIDA O SULFONAMIDAS) UTILES EN EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS, TALES COMO CANCERES, EN MAMIFEROS. ESTA INVENCION SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE USO DE TALES COMPUESTOS EN EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS EN MAMIFEROS, ESPECIALMENTE EN HUMANOS, Y A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN TALES COMPUESTOS.
GT200000069A 1999-05-19 2000-05-17 Derivados heterociclicos utiles como agentes anticancerosos. GT200000069A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13493399P 1999-05-19 1999-05-19

Publications (1)

Publication Number Publication Date
GT200000069A true GT200000069A (es) 2001-11-08

Family

ID=22465672

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200000069A GT200000069A (es) 1999-05-19 2000-05-17 Derivados heterociclicos utiles como agentes anticancerosos.

Country Status (21)

Country Link
US (1) US6380214B1 (es)
EP (1) EP1187826B1 (es)
JP (2) JP3692041B2 (es)
AR (1) AR029634A1 (es)
AT (1) ATE349440T1 (es)
AU (1) AU4137400A (es)
BR (1) BR0010746A (es)
CA (1) CA2374247C (es)
CO (1) CO5170417A1 (es)
DE (1) DE60032601T2 (es)
DZ (1) DZ3042A1 (es)
ES (1) ES2276681T3 (es)
GT (1) GT200000069A (es)
HN (1) HN2000000051A (es)
MA (1) MA26733A1 (es)
MX (1) MXPA01011920A (es)
PA (1) PA8494101A1 (es)
PE (1) PE20010152A1 (es)
TN (1) TNSN00104A1 (es)
UY (1) UY26143A1 (es)
WO (1) WO2000071532A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
WO2001057034A1 (en) 2000-02-07 2001-08-09 Bristol-Myers Squibb Co. 3-aminopyrazole inhibitors of cyclin dependent kinases
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
PL208713B1 (pl) * 2001-06-11 2011-05-31 Virochem Pharma Inc Związek stanowiący pochodną tiofenu, kompozycja farmaceutyczna zawierająca taki związek i jego zastosowanie
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
US6989451B2 (en) * 2002-06-04 2006-01-24 Valeant Research & Development Heterocyclic compounds and uses thereof
AU2003232551A1 (en) * 2002-06-13 2003-12-31 Qlt Inc. Methods of using isothiazole derivatives to treat cancer or inflammation
AU2003248896B2 (en) * 2002-07-09 2010-04-22 Fasgen, Llc Methods of treating microbial infections in humans and animals
SG169236A1 (en) * 2002-07-09 2011-03-30 Fasgen Inc Novel compunds, pharmaceutical compositions containing same, and methods of use for same
AU2003281664A1 (en) * 2002-07-25 2004-02-16 Pfizer Products Inc. Isothiazole derivatives useful as anticancer agents
US7626031B2 (en) * 2002-11-15 2009-12-01 Symphony Evolution, Inc. Substituted 3-(diarylmethylene)indolin-2-ones and methods of their use
PT1569929E (pt) 2002-12-10 2010-06-18 Virochem Pharma Inc Compostos e métodos para o tratamento ou prevenção de infecções por flavivírus
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
WO2004078723A1 (ja) * 2003-03-07 2004-09-16 Santen Pharmaceutical Co. Ltd. ４－ピリジルアルキルチオ基を置換基として有する新規化合物
CA2526617C (en) 2003-05-20 2015-04-28 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
UA84156C2 (ru) 2003-07-23 2008-09-25 Байер Фармасьютикалс Корпорейшн Фторозамещённая омега-карбоксиарилдифенилмочевина для лечения и профилактики болезней и состояний
JP4626353B2 (ja) * 2004-02-17 2011-02-09 参天製薬株式会社 置換又は無置換アミノ基を導入した４−ピリジルアルキルチオ基を有する新規環式化合物
PL1717229T3 (pl) * 2004-02-17 2011-11-30 Santen Pharmaceutical Co Ltd Nowy cykliczny związek mający grupę 4-pirydyloalkilotiolową z wprowadzoną do niej (nie)podstawioną grupą aminową
ES2368153T3 (es) * 2004-02-17 2011-11-14 Santen Pharmaceutical Co., Ltd. Nuevo compuesto cíclico que presenta un grupo 4-piridilalquiltio que presenta amino (no) sustituido introducido en el mismo.
AU2005223483B2 (en) 2004-03-18 2009-04-23 Zoetis Llc N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
EP1751139B1 (en) 2004-04-30 2011-07-27 Bayer HealthCare LLC Substituted pyrazolyl urea derivatives useful in the treatment of cancer
BRPI0514667A (pt) * 2004-08-26 2008-06-17 Pfizer Prod Inc processos para a preparação de derivados de isotiazol
JP4585978B2 (ja) * 2005-03-03 2010-11-24 参天製薬株式会社 キノリルアルキルチオ基を有する新規環式化合物
EA016071B1 (ru) * 2005-05-13 2012-01-30 Вирокем Фарма Инк. Соединения и способы лечения или предотвращения флавивирусных инфекций
US7932390B2 (en) 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
RS52874B (en) 2006-11-15 2013-12-31 Vertex Pharmaceuticals Incorporated THYOPHEN ANALYSIS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
EP2116530B1 (en) * 2007-02-26 2012-11-14 Santen Pharmaceutical Co., Ltd Novel pyrrole derivative having ureide group and aminocarbonyl group as substituents
WO2008153042A1 (ja) * 2007-06-11 2008-12-18 Kyowa Hakko Kirin Co., Ltd. 抗腫瘍剤
MX2010001636A (es) 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
JP2012531433A (ja) * 2009-06-25 2012-12-10 メドリューション リミテッド キナーゼ阻害剤としての置換複素環式化合物とその用法
CN104302640A (zh) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1950990A1 (de) * 1968-10-17 1970-05-14 Ciba Geigy Verfahren zur Herstellung von neuen triazacyclischen Verbindungen
GB1355513A (en) * 1971-04-07 1974-06-05 May & Baker Ltd Isothiazole derivatives
DE2408234A1 (de) * 1974-02-21 1975-09-04 Celamerck Gmbh & Co Kg Isothiazolylharnstoffe
US4057416A (en) * 1976-06-18 1977-11-08 Fmc Corporation 3-Alkylthio-, 3-alkylsulfinyl-, and 3-alkylsulfonylisothiazole derivatives as herbicides
US4075001A (en) * 1976-06-18 1978-02-21 Fmc Corporation 3-Aminoisothiazole derivatives as herbicides
US4059433A (en) * 1976-06-18 1977-11-22 Fmc Corporation 3-Alkoxyisothiazole derivatives as herbicides
DE3529247A1 (de) * 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung
DE3540377A1 (de) * 1985-11-14 1987-05-21 Bayer Ag Thienooxazinone, verfahren zu ihrer herstellung und ihre verwendung als leistungsfoerderer
DE3541631A1 (de) * 1985-11-26 1987-05-27 Bayer Ag Selektiv-fungizide verwendung von thienylharnstoff-derivaten
US4859699A (en) * 1987-07-20 1989-08-22 Sandoz Ltd. Substituted N-benzoyl-N'-thienylureas
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
DE4328425A1 (de) * 1993-08-24 1995-03-02 Basf Ag Acylamino-substituierte Isoxazol- bzw. Isothiazolderivate, Verfahren zu deren Herstellung und ihre Verwendung
TW276256B (es) * 1993-08-26 1996-05-21 Takeda Pharm Industry Co Ltd
ATE262902T1 (de) * 1994-11-10 2004-04-15 Millennium Pharm Inc Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose
US5792767A (en) * 1995-01-27 1998-08-11 Abbott Laboratories Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
AU7585598A (en) * 1997-05-23 1998-12-11 Bayer Corporation Raf kinase inhibitors
US6037340A (en) * 1997-05-28 2000-03-14 Cadus Pharmaceutical Corporation Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця

Also Published As

Publication number Publication date
PA8494101A1 (es) 2003-09-05
DE60032601D1 (de) 2007-02-08
JP3692041B2 (ja) 2005-09-07
CO5170417A1 (es) 2002-06-27
CA2374247A1 (en) 2000-11-30
MXPA01011920A (es) 2002-05-06
HN2000000051A (es) 2001-02-02
EP1187826A1 (en) 2002-03-20
CA2374247C (en) 2008-01-22
TNSN00104A1 (fr) 2005-11-10
BR0010746A (pt) 2002-02-13
DZ3042A1 (fr) 2004-03-27
MA26733A1 (fr) 2004-12-20
AU4137400A (en) 2000-12-12
PE20010152A1 (es) 2001-02-08
UY26143A1 (es) 2000-12-29
ATE349440T1 (de) 2007-01-15
JP2003500401A (ja) 2003-01-07
WO2000071532A1 (en) 2000-11-30
EP1187826B1 (en) 2006-12-27
US6380214B1 (en) 2002-04-30
ES2276681T3 (es) 2007-07-01
DE60032601T2 (de) 2007-11-15
AR029634A1 (es) 2003-07-10
JP2005008641A (ja) 2005-01-13

Similar Documents

Publication Publication Date Title
GT200000069A (es) Derivados heterociclicos utiles como agentes anticancerosos.
NO2022019I1 (no) Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC
HN1999000080A (es) Derivados de isotiazol utiles como agentes anticancerosos.
CU23148A3 (es) Compuestos azapoliciclicos condensados con arilo
SV1999000009A (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol ref. pg3388/sv
BR0115452A (pt) Compostos tendo atividade fungicida e processos para fabricação e uso dos mesmos
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
AR022469A1 (es) Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevas sustancias
ATE424219T1 (de) Hemmende antikörper der her3-aktivität
SE9904508D0 (sv) New compounds
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
MX9404749A (es) Heterociclos de fenilo como inhibidores de cox-2.
BR0311771A (pt) Derivados de nonano e azabiciclo-octano com atividade inibitória da ddp-iv
DK0939627T3 (da) Pentaflourbenzensulfonamider og analoger
SV1999000251A (es) Derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina ref. pcl0085/82805/bb
PA8462401A1 (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos
CL2004000969A1 (es) Compuestos derivados de alquilarilo; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de la obesidad y trastornos relacionados.
EA199800752A1 (ru) Пентафторбензолсульфонамиды и их аналоги
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
BR0002936A (pt) Compostos de biciclicarbonil-indol como agentes antiinflamatórios/analgésicos
BR0215151A (pt) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
BR0116481A (pt) Compostos de heterociclilalquilindol ou azaindol como ligandos de 5-hidroxitriptamina-6
HK1054373A1 (en) Vitamin d derivatives possessing a 22-oxa or 22-thia atom, a c17-side chain substituted by an acid, ester or amide group and a 16(17)-double bond
PA8487701A1 (es) Derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina
EE200000059A (et) Tetrahüdro-gamma-karboliinid